Navigation Links
Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage

GALVESTON, Texas, Sept. 23, 2013 /PRNewswire/ -- Today, Chrysalis BioTherapeutics, Inc., announced receipt of a $1.5m contract from the National Cancer Institute (NCI) to continue its development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. Radiotherapy is a primary tool for controlling tumor growth, yet damage to surrounding normal tissues limit the amount of radiation that can be used to kill tumors. Moreover, side-effects of radiotherapy can have long lasting effects on patients especially in the brain where radiation can affect learning, memory and physical functions. 


According to SEER Cancer Statics, nearly one in 161 people will be diagnosed with brain or nervous system cancer during their lifetime. Finding ways to mitigate damage from radiotherapy or restore neural function following radiotherapy may allow more effective cancer treatment to increase survival and improve quality-of-life for survivors.

This project is a collaboration between Chrysalis BioTherapeutics, Inc., Baylor College of Medicine (BCM), and the University of Texas Medical Branch (UTMB). Pre-clinical results indicate that Chrysalin® treatment restores radiation-damaged neural integrity and promotes neurogenesis in the hippocampus. "These effects of Chrysalin® may be very important," said Dr. Mostafa Waleed Gaber, Associate Professor at Baylor College of Medicine and Co-Director of the Small Animal Imaging Facility at Texas Children's Hospital, "especially in children where successful radiotherapy treatment of brain tumors may have life-long effects on cognitive function."

Chrysalin® is a naturally occurring regenerative peptide that is being developed by Chrysalis BioTherapeutics under world-wide license from UTMB to mitigate effects of nuclear radiation and radiotherapy.  "If we can reduce side effects of radiotherapy in the brain and other tissues, we can use more effective radiotherapy protocols to kill tumors, save lives, and improve quality-of-life." said Dr. Darrell Carney, CEO of Chrysalis BioTherapeutics, Inc.

About Chrysalis.   Chrysalis is a privately held early-clinical-stage biopharmaceutical company developing a thrombin peptide drug platform to mitigate effects of radiation, improve tissue regeneration, and treat myocardial and cardiovascular disease.  Chrysalin® was originally developed by Dr. Carney at UTMB and has been tested in human clinical trials (dermal healing and bone fracture repair) with no adverse side effects. For more information on Chrysalis visit

Media Contact: Kira Blackwell, 409-497-4083,

This research is fully funded by the National Cancer Institute.  For more information on the NCI, visit        

SOURCE Chrysalis Biotherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
2. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
3. Senior Executives of Cytyc Corporation, and Constitution Medical, Inc., Announce the Launch of ATON PARTNERS
4. An Open Letter from Sterling Scott, CEO, GrowLife, Inc., Regarding the DOJ Position Change Regarding Marijuana
5. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
6. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
7. National coordinated health care and health IT transformation event will be hosted by OCHIN, Inc., the Oregon Medical Association, and Oregon Health Network: The cHealth Innovation Symposium
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. MELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium At 8th World Congress Of Melanoma
10. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
11. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
Post Your Comments:
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is a ... filling out a survey; in many cases health professionals and patients are working together ... research on the importance of active engagement with patients and members of the public ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
Breaking Medicine News(10 mins):